Perlegen Eyes First-Half '09 Launch of Breast Cancer Dx Panel
 
Perlegen Sciences intends to release its first diagnostic product, which is focused on stratifying risk and diagnosing breast cancer, during the first half of 2009, CEO Bryan Walser said last week at the UBS Global Life Sciences Conference in New York.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.